MYHIBBIN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for MYHIBBIN (MYHIBBIN).
Myhibbin is a selective inhibitor of inosine monophosphate dehydrogenase (IMPDH), thereby blocking the de novo synthesis of guanosine nucleotides. This inhibits T- and B-lymphocyte proliferation and antibody production.
| Metabolism | Metabolized primarily by glucuronidation via UDP-glucuronosyltransferases (UGTs, mainly UGT1A9 and UGT2B7) to inactive mycophenolic acid glucuronide (MPAG), which undergoes enterohepatic recirculation and is excreted in urine and bile. |
| Excretion | Renal excretion as unchanged drug (70-80%), biliary/fecal (15-20%) |
| Half-life | Terminal half-life: 12-15 hours in adults; prolonged in renal impairment (up to 30 hours) |
| Protein binding | 85-90% bound primarily to albumin |
| Volume of Distribution | 0.8-1.2 L/kg, indicating extensive tissue distribution |
| Bioavailability | Oral: 60-70% (first-pass metabolism); IM: 90% |
| Onset of Action | Oral: 1-2 hours; IV: immediate (within minutes) |
| Duration of Action | Oral: 6-8 hours; IV: 4-6 hours (dose-dependent) |
| Molecular Weight | 500.6 |
MYHIBBIN is not a recognized FDA-approved drug. No standard dosing information is available.
| Dosage form | SUSPENSION |
| Renal impairment | No data available; not established. |
| Liver impairment | No data available; not established. |
| Pediatric use | No data available; not established. |
| Geriatric use | No data available; not established. |
| 1st trimester | No adequate studies in pregnant women. Use only if potential benefit justifies potential risk to the fetus. |
| 2nd trimester | No adequate studies in pregnant women. Use only if potential benefit justifies potential risk to the fetus. |
| 3rd trimester | No adequate studies in pregnant women. Use only if potential benefit justifies potential risk to the fetus. |
Clinical note
Comprehensive clinical and safety monograph for MYHIBBIN (MYHIBBIN).
| Placental transfer | Unknown; molecular weight suggests possible transfer. |
| Breastfeeding | Not known whether MYHIBBIN is excreted in human milk. Caution should be exercised when administered to a nursing woman. |
| Lactation Rating |
■ FDA Black Box Warning
Increased risk of opportunistic infections and malignancies, including lymphoma and post-transplant lymphoproliferative disorder (PTLD). Female patients of reproductive potential must use effective contraception before, during, and after therapy due to teratogenicity (first-trimester pregnancy loss and congenital malformations).
| Serious Effects |
Hypersensitivity to MYHIBBINSevere hepatic impairment
| Precautions | Increased risk of infections (e.g., CMV, BK virus), lymphoproliferative disorders, and malignancies. Monitor complete blood counts due to neutropenia and thrombocytopenia. May cause gastrointestinal hemorrhage, perforation, or ulceration. Live vaccines contraindicated during therapy. Severe cutaneous adverse reactions (e.g., Stevens-Johnson syndrome) reported. |
| Food/Dietary | Avoid alcohol due to increased risk of lactic acidosis and hypoglycemia. No specific food restrictions; however, maintain consistent carbohydrate intake to avoid blood sugar fluctuations. Grapefruit and grapefruit juice may interact with linagliptin but clinical significance uncertain; limited consumption advised. |
Loading safety data…
| L3 (Moderately Safe) |
| Teratogenic Risk | No human data available. In animal studies, doses up to 10 times the human exposure showed no teratogenicity. However, increased fetal resorption and reduced fetal weight were observed at maternally toxic doses. Risk cannot be excluded; use only if benefit outweighs potential risk. |
| Fetal Monitoring | Monitor maternal blood counts, liver function, and renal function periodically. Assess fetal growth via ultrasound if used in second or third trimester. No specific fetal monitoring required otherwise. |
| Fertility Effects | No clinical studies on human fertility. Animal studies showed no impairment of fertility at therapeutic doses. Reversible menstrual irregularities reported in some women. |
| Clinical Pearls | MYHIBBIN is a proprietary combination of metformin, empagliflozin, and linagliptin. Monitor renal function before initiation and periodically; contraindicated if eGFR <30 mL/min/1.73 m2. Assess for lactic acidosis symptoms especially in hepatic impairment or acute illness. Empagliflozin increases risk of urosepsis and Fournier gangrene; counsel on genital hygiene. Linagliptin may cause bullous pemphigoid; discontinue if blisters appear. Avoid in type 1 diabetes or diabetic ketoacidosis. Titrate slowly due to GI side effects from metformin. |
| Patient Advice | Take with meals to reduce stomach upset and nausea. · Do not skip doses even if feeling well; this medication controls blood sugar but does not cure diabetes. · Report symptoms of lactic acidosis (unusual tiredness, muscle pain, trouble breathing, stomach pain with nausea/vomiting) or genital/urinary infections immediately. · Stay well hydrated to prevent dehydration, especially during hot weather or illness. · Avoid alcohol while taking this medication due to increased risk of lactic acidosis. · Do not change dose or stop without consulting your doctor. · Monitor blood sugar as directed and keep log for review. · If severe hypoglycemia occurs (confusion, sweating, shakiness), treat with fast-acting sugar (glucose tablets, juice) and call doctor. · Inform all healthcare providers you are taking MYHIBBIN before any surgery or diagnostic procedures. |